logo
Plus   Neg
Share
Email

Novartis : Type 2 Diabetes Study Shows Long-term Clinical Benefits

Novartis (NVS) said that five-year VERIFY study in type 2 diabetes demonstrated long-term clinical benefits of early combination treatment with Galvus and metformin.

The company noted that early combination treatment strategy with vildagliptin (Galvus) and metformin was superior to standard of care in newly diagnosed type 2 diabetes patients.

The company said it is committed to optimizing patient management of type 2 diabetes to achieve better glycemic control and favorable long-term clinical outcomes.

Additional pre-defined secondary analyses of the VERIFY study results are ongoing and data will be disclosed over the coming months at international and local medical congresses and in scientific journals, the company said.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
The University of Phoenix has agreed to pay a record $191 million to settle Federal Trade Commission charges alleging that the university used deceptive advertisements. According to the FTC, the university used deceptive advertisements that falsely touted their relationships and job opportunities... General Motors introduced new versions of its Chevrolet Tahoe and Suburban full-size SUVs that are bigger than previous models, offer more interior space and feature more advanced technology. The new vehicles join the new Silverado and Silverado HD as part of a complete redesign of Chevrolet's full-size truck and SUV lineup within 24 months. They will go on sale in mid-2020 in North America. Apple unveiled a new feature for the Apple Card, enabling cardholders to buy a new iPhone in 24 monthly installments without paying interest. In October, during Apple's earnings call, CEO Tim Cook had announced the tech giant's plans to introduce this feature. The Apple Card, Apple's first credit card, was introduced by the tech giant in March in partnership with Goldman Sachs and Mastercard.
Follow RTT
>